PFE logo

PFIZER INC

PFENYSE
πŸ† #87 by market capEarnings Feb 2US Equity
$27.40β–Ό $0.14 (βˆ’0.51%)
Market closed Β· at close
πŸ””
Track PFE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.5%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$156.17B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
1.3%
Slowing
πŸ“ŠGross Margin
74.9%
High
πŸ’΅FCF Margin
18.5%
Healthy
βš–οΈP/S Ratio
2.5x
Cheap
Otter Score
76
Strong
No chart data available for PFE.

Trading Snapshot

Day Range
$27.36 – $28.11
52-Week Range
$23.62 – $31.44
Volume (shares)
38,285,319
Avg Volume (shares)
β€”
Shares Outstanding
5.70B
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$62.58B
Last Q Revenue
$16.58B
P/E Ratio
38.9
P/S Ratio
2.5x
EPS (TTM)
$0.70
Dividend Yield
6.24%
Dilution (1yr)
βˆ’0.3%
PFE logo

PFIZER INC

PFE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62.6Bβ–Ό βˆ’1.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.3%β–² +3.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$17.4Bβ–² +16.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9.1Bβ–Ό βˆ’7.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.69Bβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$66.3Bβ–Ό βˆ’$3.7B YoY
StockOtter Β· stockotter.space

About PFIZER INC

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

247 WallstΒ·8h ago

4 High-Yield Dividend Stocks Retirees Should Think Twice About Owning

Yields of 5% to 6.3% look like a gift when the S&P 500 barely pays 1%. But four household names are sending signals that a retiree's income check may not be as safe as the number suggests.

The Motley FoolΒ·12h ago

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson maintains a diversified business model balancing pharmaceutical innovation with a massive medical technology segment. Pfizer is undergoing a significant transition by investing heavily in oncology and o

24/7 Wall StreetΒ·1d ago

5 Dividend Stocks Yielding Over 4% Retirees Should Buy Before December

Retirees heading into year-end need two things from an income stock: a yield that tops inflation and a payout the business can comfortably fund. A big headline yield can also be the market pricing in a cut, which is the

Fool - Investing NewsΒ·1d ago

Breakfast News: When Tech Wobbles, Dividends Pay

Motley Fool analysts share their favorite dividend stocks as tech stocks wobble.

The Motley FoolΒ·2d ago

Pfizer's Launched and Acquired Drugs Grew 32% in Q3 β€” and 3 Other Reasons to Buy the Stock Before 2027

Pfizer is a well-respected drugmaker facing typical industry headwinds. The company is financially strong, and new drug development is slowly gaining traction.

Zacks Investment ResearchΒ·2d ago

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.